Rajkumar Doshi, MD
Cardiovascular Disease · Hackettstown, NJNPI 1962906578
Payments from drug & device makers
What this record shows
The money is spread across several categories — grants (51.0%), food and beverage and education — rather than concentrated in one kind of arrangement. 12 manufacturers reported payments, led by Merck at 51.0% of the total. Reporting peaked in 2021 at $1,000 and has fallen 51.0% since, to $490 in 2025. That places this record below the midpoint for cardiovascular disease clinicians in NJ, where the typical reported total is $2,633.
Across 46 payments — averaging $42.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$1K
- E.r. Squibb & Sons, L.L.C.$269
- Amgen$127
- Edwards Lifesciences$126
- Novartis$110
- Pfizer$108
- plus $222 from 6 others
What the payments were for
- Grants$1,00051%
- Food & beverage$86244%
- Education$1005%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 1 | $1,000 |
| E.r. Squibb & Sons, L.L.C. | 18 | $269 |
| Amgen | 8 | $127 |
| Edwards Lifesciences | 1 | $126 |
| Novartis | 6 | $110 |
| Pfizer | 6 | $108 |
| AstraZeneca | 1 | $100 |
| Abiomed | 1 | $31 |
| Boston Scientific | 1 | $28 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $25 |
| Abbott | 1 | $22 |
| Esperion Therapeutics, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,962 in reported general payments places this provider in the 40th percentile of 1,006 cardiovascular disease providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Atorvastatin Calcium | 12 | $203 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Hackettstown
- Marc CohenNewark$762K
- Peter FarrugiaColts Neck$600K
- Felix Dailey-SterlingGuttenberg$568K
- Ramzan ZakirNew Brunswick$342K
- Richard KovachBrowns Mills$300K
- Andrea RussoCamden$293K
- John KostisNew Brunswick$225K
- Dilip ViswanathHaddon Heights$167K
- David PowellSpringfield$162K
- Fadi ChaabanWest Orange$161K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.